[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"St Mary's Hospital, Lacor\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100632198","phase-4-vitamin-d-supplementation-among-pregnant-women-in-uganda-for-the-prevention-of-hypertensive-disorders-in-pregnancy-and-other-adverse-maternal-and-foetal-outcomes-100632198",false,"NCT07510568","Vitamin D Supplementation Among Pregnant Women in Uganda for the Prevention of Hypertensive Disorders in Pregnancy, and Other Adverse Maternal and Foetal Outcomes","Vitamin D Supplementation Among Pregnant Women in Uganda and for the Prevention of Adverse Obstetric Outcomes: a Randomized Controlled Trial","MAMA","Inclusion Criteria:\n\nWomen of age ≥ 18 years, who attend ANC services at St. Mary's Hospital Lacor, satisfying the following criteria:\n\n* with a viable intrauterine pregnancy,\n* at gestational age at recruitment between 13 weeks 0 days and 27 weeks 6 days, and\n* who consented to participate in the study.\n\nExclusion Criteria:\n\n* women already on Vitamin D treatment prescribed by a physician.","FEMALE","18 Years",{"count":20,"type":21},1980,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this randomised controlled trial is to investigate if vitamin D supplementation among pregnant women in Uganda prevents adverse maternal and foetal outcomes, with special emphasis on preeclampsia.\n\nThe main question it aims to answer is if Vitamin D supplementation, administered as oral vitamin D₃ at a dose of 2,000 IU once daily, from the time of recruitment to the time of delivery, reduces the incidence of preeclampsia, eclampsia and HELLP syndrome in pregnant women attending ANC at St. Mary's Hospital, Lacor, such incidence being monitored up to six (6) weeks after delivery.\n\nResearchers will compare the effect of oral 2.000 IU vitamin D daily (intervention group) vs. oral placebo daily (control group) on the prevalence of adverse maternal and foetal outcomes.",[27,28,29],"Preeclampsia","Eclampsia","HELLP Syndrome","NOT_YET_RECRUITING","2026-04-01",{"date":33,"type":34},"2026-04-03","ACTUAL",{"date":36,"type":21},"2026-06-01",{"date":38,"type":21},"2027-12-31",{"name":40,"class":41},"St Mary's Hospital, Lacor","OTHER",""]